There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Sarepta Therapeutics (SRPT), RegenXBio (RGNX) and Prothena Corp (PRTA) with bullish sentiments.
Sarepta Therapeutics (SRPT)
In a report released yesterday, Ravi Mehrotra from Evercore ISI assigned a Buy rating to Sarepta Therapeutics, with a price target of $200. The company’s shares opened today at $136.88.
Mehrotra wrote:
“We intend in connection with our next trial or set of trials associated with commercial material to address those issues and won’t move some of the restrictions that out of an overabundance or an abundance of caution exists within the protocol for what we call [indiscernible] (55:07) and now Study 102. So that our ultimate goal is to have the broadest possible coverage both of patients, age groups, geography but also genotype as well.”
Mehrotra has an average return of 17.9% when recommending Sarepta Therapeutics.
According to TipRanks.com, Mehrotra is ranked #274 out of 5229 analysts.
Sarepta Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $213.18, which is a 55.7% upside from current levels. In a report released yesterday, Cowen & Co. also maintained a Buy rating on the stock with a $213 price target.
See today’s analyst top recommended stocks >>
RegenXBio (RGNX)
Evercore ISI analyst Joshua Schimmer maintained a Buy rating on RegenXBio yesterday and set a price target of $79. The company’s shares opened today at $41, close to its 52-week low of $35.70.
According to TipRanks.com, Schimmer is a 5-star analyst with an average return of 11.4% and a 50.4% success rate. Schimmer covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals Inc, Akero Therapeutics Inc, and CymaBay Therapeutics.
Currently, the analyst consensus on RegenXBio is a Strong Buy with an average price target of $93.25, representing a 127.4% upside. In a report issued on July 26, Chardan Capital also reiterated a Buy rating on the stock with a $150 price target.
Prothena Corp (PRTA)
Nomura analyst Christopher Marai maintained a Buy rating on Prothena Corp on August 6 and set a price target of $19. The company’s shares opened today at $9.03, close to its 52-week low of $8.63.
Marai observed:
“Ph1 TTR Data YE19 – to Trigger Ph2s: Rare TTR to Enroll. PRTA is currently focused on ATTR-PN; in our view, a trial of PRX004 vs. SOC (tafamidis) could be attractive and rapidly enrolled, and could similarly apply to the cardiac pt population. PRTA’s mAb targets misfolded TTR and could facilitate a more rapid clinical response by clearing these species vs. knocking down production (ALNY/IONS, patisiran/inotersen) or stabilizers (PFE/EDIX, tafamidis/AG10). At least mechanistically, synergies are possible and could justify combination trials. TTR study landscape on p. 6. Progressed Pts. ALNY’s “disease reversal” is observed in early-stage patients, and a clearance MOA is likely to augment activity of knockdown approaches. Silencers (ALNY’s and stabilizers (PFE’s tafamidis) are predicted to halt disease progression by preventing the formation of additional misfolded TTR plaques.”
According to TipRanks.com, Marai is a 4-star analyst with an average return of 7.5% and a 50.1% success rate. Marai covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Voyager Therapeutics Inc, and Protagonist Therapeutics.
Prothena Corp has an analyst consensus of Hold, with a price target consensus of $13.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
